Targets › CCR7
1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2027.
Receptor for the MIP-3-beta chemokine. Probable mediator of EBV effects on B-lymphocytes or of normal lymphocyte functions. (UniProt, P32248)
Open in Phaseline: the race on CCR7, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Catapult Therapeutics | CAP-100 humanized antibody against C-C-chemokine receptor 7 (CCR7) | CCR7 | Phase 1 | Lymphocytic Leukemia, Chronic | Jan 2027 |
Lymphocytic Leukemia, Chronic (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.